Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects
Silvia Höfer(University Hospital of Zurich), Christina Fotopoulou(Ovarian Cancer Action), Benedikt M. Schaarschmidt(Essen University Hospital), Jendrik Hardes(Ruhrlandklinik), Katrin Scheinemann(University of Lucerne), Hans Gelderblom(Leiden University Medical Center), Bernadette Liegl‐Atzwanger(Medical University of Graz), Rick L. Haas(Leiden University Medical Center), Chantal Pauli(University of Zurich), Joanna Szkandera(Medical University of Graz), Peter Hohenberger(University of Mannheim), Peter Reichardt(Helios Hospital Berlin-Buch), Eva Wardelmann(University Hospital Münster), Sylvie Bonvalot(Dana-Farber Cancer Institute), Aisha Miah(Institute of Cancer Research), Beata Bode‐Lesniewska(Luzerner Kantonsspital), Wolfgang G. Kunz(LMU Klinikum), Jens Jakob(Heidelberg University), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Dimosthenis Andreou(Klinik und Poliklinik für Psychosomatik und Psychotherapie), Lars H. Lindner(Center for Environmental Health), Andreas Leithner(Medical University of Graz)
Cited by 2
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k